| Booster Vaccine for Yellow Fever (NCT05332197) | London School of Hygiene and Tropical Medicine | 2022-05-16 |
| Trial of an Inactivated Yellow Fever Virus Vaccine (NCT05172544) | Najit Technologies, Inc. | 2022-01-13 |
| Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection (NCT04267809) | Singapore General Hospital | 2021-10-22 |
| Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia (NCT05011123) | Sanofi Pasteur, a Sanofi Company | 2021-10-07 |
| Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA (NCT04942210) | Sanofi Pasteur, a Sanofi Company | 2021-07-01 |
| Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC (NCT04235361) | University of Stirling | 2021-01-15 |
| The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination (NCT04269265) | University of Minnesota | 2020-07-01 |
| A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 (NCT03891420) | BioCryst Pharmaceuticals | 2020-04-09 |
| Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine (NCT04059471) | University of Oxford | 2019-11-11 |
| Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine (NCT01290055) | Sri Edupuganti | 2019-04-15 |
| Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old (NCT03725618) | Centers for Disease Control and Prevention | 2018-11-01 |
| Evaluation of an Infant Immunization Encouragement Program in Nigeria (NCT03870061) | GiveWell | 2018-07-01 |
| Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea (NCT03541694) | Sanofi Pasteur, a Sanofi Company | 2018-04-11 |
| Yellow Fever Vaccine on Statin/ Non Statin Subjects (NCT03116802) | Singapore General Hospital | 2017-03-08 |
| A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (NCT02743455) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-07-05 |
| Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children (NCT02990182) | Oswaldo Cruz Foundation | 2015-04-01 |
| Immunity After Two Doses of Yellow Fever Vaccine (NCT02572518) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2014-05-01 |
| The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans (NCT01943305) | Singapore General Hospital | 2013-10-01 |
| Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine (NCT01488890) | Sanofi Pasteur, a Sanofi Company | 2011-12-06 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (NCT01466387) | Novartis | 2011-11-01 |
| Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers (NCT01436396) | Sanofi Pasteur, a Sanofi Company | 2011-09-07 |
| The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (NCT01426243) | French National Agency for Research on AIDS and Viral Hepatitis | 2011-07-01 |
| Trial of Yellow Fever Inactivated Vaccine (NCT00995865) | GE Healthcare | 2010-01-01 |
| Human Immune Responses to Yellow Fever Vaccination (NCT00694655) | Emory University | 2008-05-01 |
| Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults (NCT00616356) | Rockefeller University | 2007-12-01 |
| Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) (NCT00982137) | Sanofi | 2004-07-01 |